Genzyme Pharmaceuticals, a business unit of Genzyme Corporation, and Brookwood Pharmaceuticals, Inc., today announced a broad collaboration to develop novel drug delivery solutions, with an initial focus on peptide delivery.
CAMBRIDGE, Mass. and BIRMINGHAM, Ala., May 2,2006,/PRNewswire/– Genzyme Pharmaceuticals, a business unit of Genzyme Corporation, and Brookwood Pharmaceuticals, Inc., today announced a broad collaboration to develop novel drug delivery solutions, with an initial focus on peptide delivery. The partnership offers customized solutions for parenteral formulations by combining expertise in design for peptide delivery, peptide synthesis, and drug delivery technologies.
The 'Design for Peptide Delivery' approach optimizes peptide physical and chemical properties early on in drug development, so as to match a peptide with the properties of microparticles, implants and other drug delivery formulations required for optimal drug delivery. Combining the capabilities and knowledge of Genzyme and Brookwood in parallel design of peptide and delivery systems will result in clients developing sophisticated pharmaceutical products that will benefit the patient.
